• Home
  • News
  • Stephenson Harwood advises Oxford Biomedica on gene therapy collaboration

24 Nov 2020

Stephenson Harwood advises Oxford Biomedica on gene therapy collaboration


Law firm Stephenson Harwood LLP has advised gene and cell therapy company Oxford Biomedica on its collaboration with biopharmaceutical company PhoreMost, to develop next-generation CAR-T cell therapies.

CAR-T therapies, or chimeric antigen receptor T-cell therapies, modify T-cells to recognise cancer cells in order to more effectively target and destroy them.

PhoreMost, a UK-based business dedicated to developing drugs against intractable disease targets, will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica's LentiVector® gene therapy delivery system. The programme will initially focus on CAR-T therapy and aims to develop next-generation cell therapies with significantly improved efficacy and durability.

The Stephenson Harwood team advising Oxford Biomedica was led by partner Alexandra Pygall, and assisted predominantly by Anne Stoffels.



Alexandra Pygall

Alexandra Pygall

T:  +44 20 7809 2137 M:  +44 7881 314 566 Email Alexandra | Vcard Office:  London



Andrew Rieley
Head of communications and PR
T: +44 20 7809 2886
Email Andrew
  • Related Sectors
  • Related Locations